Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Antiviral Activity of Voxilaprevir in Chronic Hepatitis C
NCT02185794Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2014
- Primary completion
- Dec 2014
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of voxilaprevir in hepatitis C (HCV) (16 arms), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants Experiencing Treatment Emergent Adverse Events, Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities and 1 more. Started Jun 2014; status: completed.
02
Drugs
voxilaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02185794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02185794.